605 related articles for article (PubMed ID: 33328215)
1. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.
Wang D; Prager BC; Gimple RC; Aguilar B; Alizadeh D; Tang H; Lv D; Starr R; Brito A; Wu Q; Kim LJY; Qiu Z; Lin P; Lorenzini MH; Badie B; Forman SJ; Xie Q; Brown CE; Rich JN
Cancer Discov; 2021 May; 11(5):1192-1211. PubMed ID: 33328215
[TBL] [Abstract][Full Text] [Related]
2. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract][Full Text] [Related]
3. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.
Wang S; Wei W; Yuan Y; Sun B; Yang D; Liu N; Zhao X
J Transl Med; 2023 Jul; 21(1):493. PubMed ID: 37481592
[TBL] [Abstract][Full Text] [Related]
5. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy.
Chen C; Jing W; Chen Y; Wang G; Abdalla M; Gao L; Han M; Shi C; Li A; Sun P; Jiang X; Yang Z; Zhang S; Zhang J; Tang C; Liu Y; Zhang R; Xu F; Dong B; Li X; Liu M; Qiang B; Sun Y; Wei X; Li J; Hu Q; Jiang X
Sci Transl Med; 2022 Aug; 14(656):eabn1128. PubMed ID: 35921473
[TBL] [Abstract][Full Text] [Related]
6. Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products.
Logun M; Colonna MB; Mueller KP; Ventarapragada D; Rodier R; Tondepu C; Piscopo NJ; Das A; Chvatal S; Hayes HB; Capitini CM; Brat DJ; Kotanchek T; Edison AS; Saha K; Karumbaiah L
Cytotherapy; 2023 Jun; 25(6):670-682. PubMed ID: 36849306
[TBL] [Abstract][Full Text] [Related]
7. Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells.
Qiu Z; Zhao L; Shen JZ; Liang Z; Wu Q; Yang K; Min L; Gimple RC; Yang Q; Bhargava S; Jin C; Kim C; Hinz D; Dixit D; Bernatchez JA; Prager BC; Zhang G; Dong Z; Lv D; Wang X; Kim LJY; Zhu Z; Jones KA; Zheng Y; Wang X; Siqueira-Neto JL; Chavez L; Fu XD; Spruck C; Rich JN
Cancer Discov; 2022 Feb; 12(2):502-521. PubMed ID: 34615656
[TBL] [Abstract][Full Text] [Related]
8. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
9. Targeting of the alpha
Cobb DA; de Rossi J; Liu L; An E; Lee DW
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
Wakimoto H; Mohapatra G; Kanai R; Curry WT; Yip S; Nitta M; Patel AP; Barnard ZR; Stemmer-Rachamimov AO; Louis DN; Martuza RL; Rabkin SD
Neuro Oncol; 2012 Feb; 14(2):132-44. PubMed ID: 22067563
[TBL] [Abstract][Full Text] [Related]
11. Prospective approaches to enhancing CAR T cell therapy for glioblastoma.
Choi SI; Yin J
Front Immunol; 2022; 13():1008751. PubMed ID: 36275671
[TBL] [Abstract][Full Text] [Related]
12. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.
Tang N; Cheng C; Zhang X; Qiao M; Li N; Mu W; Wei XF; Han W; Wang H
JCI Insight; 2020 Feb; 5(4):. PubMed ID: 31999649
[TBL] [Abstract][Full Text] [Related]
13. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
14. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
Dufva O; Koski J; Maliniemi P; Ianevski A; Klievink J; Leitner J; Pölönen P; Hohtari H; Saeed K; Hannunen T; Ellonen P; Steinberger P; Kankainen M; Aittokallio T; Keränen MAI; Korhonen M; Mustjoki S
Blood; 2020 Feb; 135(9):597-609. PubMed ID: 31830245
[TBL] [Abstract][Full Text] [Related]
15. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
16. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.
Kim KH; Seol HJ; Kim EH; Rheey J; Jin HJ; Lee Y; Joo KM; Lee J; Nam DH
Neuro Oncol; 2013 Feb; 15(2):161-71. PubMed ID: 23258844
[TBL] [Abstract][Full Text] [Related]
17. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
18. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy.
Ye L; Park JJ; Peng L; Yang Q; Chow RD; Dong MB; Lam SZ; Guo J; Tang E; Zhang Y; Wang G; Dai X; Du Y; Kim HR; Cao H; Errami Y; Clark P; Bersenev A; Montgomery RR; Chen S
Cell Metab; 2022 Apr; 34(4):595-614.e14. PubMed ID: 35276062
[TBL] [Abstract][Full Text] [Related]
19. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
[No Abstract] [Full Text] [Related]
20. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
